Inhibition of protein translocation at the endoplasmic reticulum promotes activation of the unfolded protein response by McKibbin, Craig et al.
Edith Cowan University 
Research Online 
ECU Publications 2012 
1-1-2012 
Inhibition of protein translocation at the endoplasmic reticulum 
promotes activation of the unfolded protein response 
Craig McKibbin 
Alina Mares 
Michela Piacenti 
Helen Williams 
Peristera Roboti 
See next page for additional authors 
Follow this and additional works at: https://ro.ecu.edu.au/ecuworks2012 
 Part of the Biological Factors Commons 
10.1042/BJ20111220 
McKibbin, C., Mares, A., Piacenti, M., Williams, H., Roboti, P., Puumalainen, M., Callan, A. C., Lesiak-Mieczkowska, K., 
Linder, S., Harant, H., High, S., Flitsch, S., Whitehead, R., & Swanton, E. (2012). Inhibition of protein translocation at 
the endoplasmic reticulum promotes activation of the unfolded protein response. Biochemical Journal, 442(3), 
639-648. Available here 
This Journal Article is posted at Research Online. 
https://ro.ecu.edu.au/ecuworks2012/483 
Authors 
Craig McKibbin, Alina Mares, Michela Piacenti, Helen Williams, Peristera Roboti, Marjo Puumalainen, Anna 
Callan, Karolina Lesiak-Mieczkowska, Stig Linder, Hanna Harant, Stephen High, Sabine Flitsch, Roger 
Whitehead, and Eileithyia Swanton 
This journal article is available at Research Online: https://ro.ecu.edu.au/ecuworks2012/483 
Biochem. J. (2012) 442, 639–648 (Printed in Great Britain) doi:10.1042/BJ20111220 639
Inhibition of protein translocation at the endoplasmic reticulum promotes
activation of the unfolded protein response
Craig MCKIBBIN*1, Alina MARES*, Michela PIACENTI†, Helen WILLIAMS†, Peristera ROBOTI*, Marjo PUUMALAINEN*,
Anna C. CALLAN*, Karolina LESIAK-MIECZKOWSKA‡, Stig LINDER‡, Hanna HARANT§, Stephen HIGH*, Sabine L. FLITSCH‖,
Roger C. WHITEHEAD†2 and Eileithyia SWANTON*2
*Faculty of Life Sciences, University of Manchester, Michael Smith Building, Oxford Road, Manchester M13 9PT, U.K., †School of Chemistry, University of Manchester, Oxford Road,
Manchester M13 9PL, U.K., ‡Department of Oncology and Pathology, Karolinska Institute, 171 76 Stockholm, Sweden, §Ingenetix GmbH, Simmeringer Hauptstrasse 24, 1110 Vienna,
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Selective small-molecule inhibitors represent powerful tools for
the dissection of complex biological processes. ESI (eeyarestatin
I) is a novel modulator of ER (endoplasmic reticulum)
function. In the present study, we show that in addition to
acutely inhibiting ERAD (ER-associated degradation), ESI causes
production of mislocalized polypeptides that are ubiquitinated
and degraded. Unexpectedly, our results suggest that these
non-translocated polypeptides promote activation of the UPR
(unfolded protein response), and indeed we can recapitulate
UPR activation with an alternative and quite distinct inhibitor of
ER translocation. These results suggest that the accumulation
of non-translocated proteins in the cytosol may represent a novel
mechanism that contributes to UPR activation.
Key words: eeyarestatin, endoplasmic reticulum, non-translo-
cated protein, Sec61, unfolded protein response.
INTRODUCTION
In eukaryotic cells, the ER (endoplasmic reticulum) is the major
site for the synthesis of membrane and secretory proteins. These
are co-translationally translocated across or integrated into the
membrane through a proteinaceous channel, the Sec61 complex
[1]. Once exposed to the ER lumen, polypeptides are folded,
assembled and may undergo post-translational modification, such
as N-linked glycosylation, prior to being transported to their site of
function. However, folding is an intrinsically error-prone process,
and polypeptides may also fail to attain their native state due to
errors in translation, genetic mutation, absence of partner subunits
or unfavourable environmental conditions. Such misfolded or
misassembled polypeptides are potentially harmful, and in order
to prevent their deployment within the cell, they are retained in
the ER by a quality control system [2]. To avoid congestion and
potential interference with productive protein folding, misfolded
proteins must be cleared from the ER, and this is achieved
via a process known as ERAD (ER-associated degradation) [3].
ERAD is mediated by the cytosolic proteasome, which means
that proteins selected for ERAD must be retrotranslocated back
across the ER membrane into the cytosol prior to degradation [3].
Ubiquitin ligases at the cytosolic face of the ER membrane ubi-
quitinate the ERAD substrate, directing it to the UPS (ubiquitin–
proteasome system). Ubiquitination also attracts p97, an ATPase
that facilitates extraction of many ERAD substrates from the
ER membrane. The ERAD substrate is then deglycosylated
and deubiquitinated, before entering the catalytic core of the
proteasome where it is broken down into small peptides [3].
Situations that perturb the balance between protein synthesis,
folding and degradation pathways (termed proteostasis [4]), can
lead to a build-up of misfolded proteins in the ER, causing
ER stress. Eukaryotic cells possess a signalling network known
as the UPR (unfolded protein response), to detect and manage
such imbalances in ER proteostasis [5]. UPR signalling pathways
function to reduce the rate of protein synthesis and up-regulate
the expression of chaperones and ERAD factors, thereby reducing
levels of misfolded proteins in the ER and restoring homoeostasis.
If homoeostasis is not re-established, prolonged activation of
the UPR can initiate programmed cell death [5]. Disturbances
in ER proteostasis and UPR signalling are implicated in the
pathogenesis of a diverse range of diseases, including diabetes
mellitus, cancer, neurodegeneration, and bone and joint diseases,
as well as classical ER protein folding diseases such as cystic
fibrosis [6]. As a result, there is considerable interest in the
therapeutic potential of selective small molecules to manipulate
these pathways in order to ameliorate disease [4].
The small molecules ESI (eeyarestatin I) and ESII (eeyarestatin
II) are ERAD inhibitors, first identified in a high-throughput
screen based on stabilization of GFP (green fluorescent protein)-
tagged MHC I heavy chain, which is degraded via an ERAD-
like pathway in cells expressing the viral protein US11 [7]. The
degradation of a conventional ERAD substrate, TCRα (T-cell
receptor α subunit), was also inhibited by ESI [7], and it was
suggested that the compound acts at an early stage in the ERAD
pathway, prior to retrotranslocation. Subsequent work provided
evidence that a later stage in ERAD, namely the p97 ATPase and
an associated deubquitinating activity, may also be inhibited by
ESI [8,9]. ESI has also been shown to activate the UPR and induce
cell death [10]. Intriguingly, the cytotoxic activity of ESI appears
to be particularly effective against cancer cells, and synergizes
with that of bortezomib (Velcade), a proteasome inhibitor with
proven anticancer properties [10]. Together with accumulating
evidence that UPR activation plays a role in a variety of
Abbreviations used: CHX, cycloheximide; cpd A, translocation inhibitor compound A; DMEM, Dulbecco’s modified Eagle’s medium; DTT, dithiothreitol;
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like 1; ERAD, ER-associated degradation; ES, eeyarestatin; HEK, human embryonic kidney; IP, immunoprecipitation; IRE1, inositol-requiring enzyme 1;
PDI, protein disulfide-isomerase; PERK, PKR (double-stranded-RNA-dependent protein kinase)-like ER kinase; PS2, proteasome inhibitor 2; RT, reverse
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cancers [11], these observations highlight a potential therapeutic
application for ESI-related compounds. Both activation of the
UPR and perturbation of cellular ubiquitin homoeostasis have
been proposed to cause ESI cytotoxicity [10]. However, the
underlying molecular mechanism(s) through which ESI activates
the UPR and exerts its effects is not yet clear.
We have previously shown that ESI inhibits Sec61-mediated
translocation of a range of proteins across the ER membrane,
albeit to various degrees depending on the precursor studied
[12]. The consequences of ESI-dependent perturbations of ER
translocation in cells are not known, raising the possibility that
inhibition of translocation contributes to the potent cellular effects
of ESI. In the present study we show that ESI treatment results in
the production of mislocalized membrane and secretory proteins,
and demonstrate that accumulation of these species correlates with
activation of the UPR. Using an alternative inhibitor of transloca-
tion, we provide evidence that accumulation of non-translocated
polypeptides in the cytosol promotes activation of the UPR.
EXPERIMENTAL
Materials
The M2 anti-FLAG antibody was from Sigma–Aldrich. The P4D1
anti-ubiquitin antibody was from Santa Cruz Biotechnology.
Derlin-1 and PDI (protein disulfide-isomerase) polyclonal rabbit
antisera were made by Eurogentec. Anti-p97 antiserum was from
Professor Bernhard Dobberstein (Center for Molecular Biology,
University of Heidelberg, Heidelberg, Germany). Plasmids
encoding TCRα were from Professor Ron Kopito (Department
of Biology, Stanford University, Stanford, CA, U.S.A.) and
Professor Emmanuel Wiertz (Leiden University, Leiden, The
Netherlands). Bovine opsin cDNA was subcloned from the pZEO
vector into pcDNA5/FRT/TO (Invitrogen). The preprolactin–
mCherry construct was from Professor Viki Allan (Faculty of
Life Sciences, University of Manchester, Manchester, U.K.).
Synthesis of ESI, ESII and ESR35
Synthesis of the ESs (see the Supplementary methods
section at http://www.BiochemJ.org/bj/442/bj4420639add.htm)
commenced with nitroso-compound 1 (see Supplementary Fig-
ure S1 at http://www.BiochemJ.org/bj/442/bj4420639add.htm),
which was prepared in a straightforward fashion by the reaction
of iso-butene with nitrosyl chloride (generated in situ from iso-
amyl nitrite and HCl) [13]. The reaction of compound 1 with
methyl glycinate proceeded smoothly to give a very good yield of
oximino ester 2 [14]. Exposure of compound 2 to two equivalents
of 4-chlorophenyl isocyanate or 1-naphthyl isocyanate gave the
bis-adducts 3a and 3b [3], which were subsequently converted
into their corresponding acyl hydrazides 4a and 4b by treatment
with an aqueous methanolic solution of hydrazine (acyl hydrazide
4a is the compound also referred to as inactive analogue ESR35).
Finally, condensation of hydrazides 4a and 4b with E-3-(5-nitro-
2-furyl)acrylaldehyde in methanol gave the corresponding ESs
(ESI and ESII) in excellent yields. The double-bond geometry of
the final products was indicated as E by the magnitude of the
vicinal coupling constant between the olefinic protons (15.8 Hz
for ESI and 15.4 Hz for ESII).
Cell culture and transfection
HeLa cells were cultured in DMEM (Dulbecco’s modified Eagle’s
medium) containing 10% (v/v) FBS (fetal bovine serum) and
2 mM L-glutamine. Cells were transfected using LipofectamineTM
2000 (Invitrogen) and used in experiments after 24 h.
Treatment with compounds
Stock solutions (10 mM) of ESR35, ESII, ESI, cpd A (translocation
inhibitor compound A) and PS2 (proteasome inhibitor 2;
benzyloxycarbonyl-Leu-Leu-Phe-aldehyde; Calbiochem) were
made up in DMSO. ESR35, ESII and ESI were added to a final
concentration of 8 μM, PS2 and cpd A to 10 μM, and CHX
(cycloheximide) to 100 μg/ml, then cells were incubated at 37 ◦C.
Metabolic labelling and IP (immunoprecipitation)
Cells were incubated in DMEM lacking methionine and cysteine
(Invitrogen) for 20 min, and were labelled with 22 μCi/ml
EasyTag [35S]Met/Cys (PerkinElmer) for 40 min at 37 ◦C. Cells
were washed twice in PBS and either harvested immediately
or chased in DMEM supplemented with 2.5 mM unlabelled
methionine/cysteine plus the indicated compounds. Cells were
harvested in 50 μl of ice-cold IP buffer (140 mM NaCl, 10 mM
Tris/HCl, pH 7.5, 1 mM EDTA and 1% Triton X-100) plus
protease inhibitor cocktail (Sigma). For IP, lysates were denatured
in 1% SDS, then 5 vol. of IP buffer containing 10 mM non-
radioactive methionine/cysteine, 1 mM PMSF and 4% pansorbin
(Calbiochem) was added. Samples were rotated for 1 h at 37 ◦C,
centrifuged at 15000 g for 10 min, and the supernatant was
incubated overnight at 4 ◦C with an anti-FLAG antibody. Immune
complexes were collected on Protein A–Sepharose beads, washed
with IP buffer, eluted in reducing SDS/PAGE sample buffer and
resolved by SDS/PAGE. Radioactive gels were analysed by FLA-
3000 phosphorimaging (Fuji) and quantified using AIDA v3.52
software (Raytest Isotopenmessgerate).
Western blotting
To detect polyubiquitinated material, cells cultured in 12-well
dishes were lysed in 50 μl of IP buffer and then denatured
in SDS/PAGE sample buffer at 70 ◦C for 10 min. Half of the
sample was run on SDS/10% PAGE gels, analysed by blotting
with an anti-ubiquitin antibody and then visualized by enhanced
chemiluminescence.
XBP1 (X-box-binding protein 1) splicing
Total RNA was extracted using TRIzol® reagent (Invitrogen), and
first-strand cDNA was synthesized with an oligo-p(dT)15 primer.
cDNA was used as a template for PCR using primers flanking
the XBP-1 intron (FWD, 5′-ACAGCGCTTGGGGATGGATG-3′;
REV, 5′-TGACTGGGTCCAAGTTGTCC-3′), and PCR products
were analysed on 2% agarose gels.
Fluorescence microscopy
HeLa cells incubated with 8 μM ESI in the medium for 0–
8 h were fixed in methanol for 4 min at − 20 ◦C, then probed
with primary antibodies against PDI and fluorophore-conjugated
secondary antibodies (Molecular Probes). For visualization
of preprolactin–mCherry, HeLa cells transfected using JetPEI
reagent (Peqlab), were incubated with 100 μg/ml CHX for 3 h
at 37 ◦C. Cells were washed three times for 1 min with 1 ml
of PBS, then treated with 8 μM ESI, 10 μM PS2 or 8 μM
ESI and 10 μM PS2 for 6 h. Following treatment, cells were
washed in PBS and fixed in 3% paraformaldehyde in PBS for
25 min at room temperature (21–23 ◦C). Images were obtained
c© The Authors Journal compilation c© 2012 Biochemical Society
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using an Olympus BX60 upright microscope with a MicroMax
cooled charge-coupled device camera (Roper Scientific) driven
by Metamorph software (Universal Imaging Corporation).
Subcellular fractionation and EndoH (endoglycosidase H) treatment
Cells in 10 cm dishes were rinsed twice in PBS, harvested by
scraping and resuspended in 100 μl of hypotonic buffer (20 mM
Hepes, pH 7.6, 5 mM KCl, 2.5 mM EDTA and 1 mM PMSF) on
ice. Cells were sonicated for three 10 s pulses in a sonicating
waterbath. Lysates were centrifuged at 50000 g for 30 min at
4 ◦C. The membrane pellet was resuspended in 100 μl of 100 mM
Na2CO3, pH 11.5, incubated on ice for 20 min, then centrifuged
at 100000 g for 1 h at 4 ◦C. The supernatant was removed, and the
pellet was solubilized in 100 μl of IP buffer for 10 min at 4 ◦C,
followed by a final centrifugation step at 100000 g for 1 h at 4 ◦C.
The supernatant was removed and the Triton X-100-insoluble
pellet was resuspended in IP buffer containing 0.1% SDS. Opsin
was immunoprecipitated from the carbonate supernatant, Triton
X-100 supernatant and Triton X-100-insoluble fractions, and was
resolved by SDS/PAGE. Where indicated, immunoprecipitated
material was incubated with 500 units of EndoH (New England
Biolabs) for 2 h at 37 ◦C.
RESULTS
ESI induces accumulation of polyubiquitinated proteins and
induces ER stress
ESI, ESII and a related compound ESR35, designed to provide a
negative control treatment (cf. [9]), were synthesized according
to the scheme outlined in Supplementary Figure S1. The inhibitory
effect of ESI on the ERAD pathway was confirmed in two
different human cell lines (see Supplementary Figure S2 at
http://www.BiochemJ.org/bj/442/bj4420639add.htm). Notably,
we found that acute (< 1 h) treatment of cells with ESI inhibited
degradation of the model substrate TCRα (Supplementary Figure
S2A), showing that the action of ESI on ERAD is rapid
and does not require prolonged treatment. In contrast, ESII
treatment did not reproducibly delay TCRα degradation, and
ESR35 had no detectable inhibitory effect (Supplementary Figure
S2). ESI treatment also resulted in the appearance of substantial
amounts of higher-molecular-mass forms of the model ERAD
substrate (Supplementary Figure S2B). Less pronounced high-
molecular-mass species were also visible in cells treated with
a proteasome inhibitor (PS2) and at the start of the chase in
untreated cells (Supplementary Figure S2B), suggesting that
they might represent polyubiquitinated forms of TCRα en
route to degradation. Consistent with this interpretation, the
total levels of polyubiquitinated proteins detected in cells were
also markedly increased upon ESI treatment (Figure 1A, lane
4, and Supplementary Figure S2C). A similar, although less
pronounced, effect was observed following treatment with ESII
and PS2 (Figure 1A, lanes 3 and 5), whereas ESR35 had no
discernable effect (Figure 1A, lane 2). These high-molecular-mass
polyubiquitin conjugates accumulated with time, and became
apparent after 1 h of exposure to ESI (Figure 1B). Increased
levels of polyubiquitinated material following ESI treatment have
been observed previously and have been proposed to reflect an
inhibition of deubiquitination [8].
Consistent with previous work [10], we also found that ESI
induced ER stress in cultured cells. Splicing of Xbp1 mRNA,
an early event in the IRE1 (inositol-requiring enzyme 1) branch
of the UPR can be measured using RT (reverse transcription)–
PCR. A single PCR product, representing the unspliced
mRNA, was observed in DMSO-treated cells (Figure 1C,
lane 2). A faster-migrating product, representing spliced Xbp1
mRNA, was apparent in cells treated with the reducing
agent DTT (dithothreitol) to perturb oxidative protein folding
(Figure 1C, lane 1). ESI also induced Xbp1 mRNA splicing (Fig-
ure 1C, lane 5), showing that treatment with this compound
resulted in activation of IRE1. In contrast, no spliced Xbp1 was
detected in cells treated with ESII or ESR35 (Figure 1C, lanes
3 and 4), consistent with the minor effect of these compounds
on ERAD and polyubiquitination (Supplementary Figure S2 and
Figure 1A). The response to ESI did not require prolonged
treatment with ESI, and spliced Xbp1 was evident after 4 h
(Figure 1D). Activation of the PERK [PKR (double-stranded-
RNA-dependent protein kinase)-like ER kinase] branch of the
UPR results in phosphorylation of eIF2α (eukaryotic initiation
factor 2α), resulting in a decrease in the rate of protein synthesis
under conditions of ER stress, as observed following treatment
with the reducing agent DTT to perturb oxidative protein folding
(Figure 1E, cf. lanes 1 and 2). Phosphorylation of eIF2α occurred
rapidly upon ESI treatment (Figure 1E, bottom two panels), and
this effect correlated with a decrease in total protein synthesis
(Figure 1E, top panel, lanes 3–8), showing that the PERK
branch of the UPR was also activated. Similar effects of ESI
were also observed in HEK (human embryonic kidney)-293
cells (see Supplementary Figure S3 at http://www.BiochemJ.
org/bj/442/bj4420639add.htm). Interestingly, ESI treatment
resulted in a more pronounced phosphorylation of eIF2α and
greater translational attenuation in HEK cells than in HeLa cells
(Supplementary Figure S3), suggesting that sensitivity to ESI can
vary between cell types (cf. [10]).
Our recent work suggests that ESI delays certain intracellular
trafficking pathways [13], and we therefore examined the effect
of the ES compounds on cell morphology. Interestingly, large
vacuole-like structures developed within 4–8 h of treatment
with ESI (Figure 1F, arrows), and these were also apparent
by immunofluorescence microscopy using an antibody specific
for ER-localized proteins (Figure 1G), suggesting that these
structures were derived from the ER. ESR35 had no obvious effect
on cell morphology (Figure 1F), and although no effect of ESII
was visible within 8 h (Figure 1F), prolonged treatment (12–
16 h) did cause the appearance of such vacuoles (results not
shown). A similar swelling of the ER occurs during paraptosis
[14], a non-apoptotic form of cell death, and has also been
observed under conditions of chronic ER stress [15,16]. Hence
these changes in ER structure may reflect ESI-induced ER stress
and/or commitment to cell death.
Inhibition of translocation promotes ER stress
The mechanisms through which ESI induces ER stress are
not known, although inhibition of ERAD and/or perturbation
of ubiquitin homoeostasis could potentially play a role [10].
Indeed, inhibition of the proteasome is able to induce
activation of the UPR in a variety of cell types (e.g. [17]).
Interestingly, however, treatment of HeLa cells with PS2
for 8 h failed to induce Xbp1 mRNA splicing (Figure 2A,
lane 3), despite causing a clear build-up of polyubiquitinated
species and profound inhibition of ERAD (Figure 1A and
Supplementary Figure S2). Similarly, Xbp1 splicing was not
observed in cells treated with an alternative proteasome inhibitor
MG132 (Figure 2A, lane 4), or in response to a small
molecule that inhibits protein deubiquitination (NSC687852)
(Figure 2A, lane 5), and causes a pronounced accumulation of
polyubiquitin adducts [18,19] (see Supplementary Figure S4A
at http://www.BiochemJ.org/bj/442/bj4420639add.htm). Thus
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Figure 1 Cellular effects of ES compounds
(A) HEK cells were treated for 8 h with DMSO, 8 μM ESR35, ESII or ESI, or 10 μM PS2, and lysates were analysed by blotting with an anti-ubiquitin (Ub) antibody. (B) HeLa cells were treated with
DMSO for 4 h or 8 μM ESI for the time indicated, and lysates were analysed by blotting with an anti-ubiquitin antibody. (C) HeLa cells were treated with 2 mM DTT for 2 h, DMSO, or 8 μM ESR35,
ESII or ESI for 8 h. Xbp1 mRNA splicing was determined by RT–PCR. PCR products corresponding to unspliced (u) and spliced (s) Xbp1 mRNA are indicated. (D) HeLa cells were treated with 8 μM
ESI for the time indicated and Xbp1 splicing was determined as above. (E) HeLa cells treated with 10 mM DTT for 30 min or 8 μM ESI for the time indicated were labelled with [35S]Met/Cys for
40 min. Lysates were analysed by phosphorimaging (top panel), or blotting with anti-peIF2α (phospho-eIF2α) or anti-eIF2α antibodies (bottom two panels). In (B and E) the molecular mass in kDa
is indicated on the left-hand side. (F) HeLa cells were treated with DMSO or 8 μM ESR35, ESII or ESI for 8 h then visualized by phase-contrast microscopy. Arrows indicate vacuolar structures. (G)
HeLa cells were treated with 8 μM ESI for the time indicated, fixed, stained with anti-PDI and fluorescently labelled secondary antibodies, and examined by fluorescence microscopy.
neither blockade of ERAD nor perturbation of global ubiquitin
homoeostasis (using a variety of different inhibitors) activated
the UPR in HeLa cells over this time course. In contrast,
parallel treatment with ESI induced a robust ER stress response
(Figure 2A, lane 2). These results are significant as they suggest
that ESI does not induce ER stress solely by blocking degradation
of ERAD substrates or disrupting the UPS [10]. We therefore
considered the alternative possibility that the ability of ESI
to activate UPR was related to its ability to perturb protein
translocation [12]. In order to test this hypothesis, we used a
second small-molecule inhibitor of co-translational translocation
(referred to in the present study as cpd A), derived from
a naturally occurring cyclic depsipeptide [20]. Like ESI, the
cyclodepsipeptide inhibitors cause a wide-ranging inhibition
of translocation when used at low micromolar concentrations
[21,22], but are structurally distinct and target a different stage
of Sec61-mediated protein translocation across the ER membrane
[20,23]. Strikingly, treatment of HeLa cells with this translocation
inhibitor also induced Xbp1 mRNA splicing on a timescale
comparable with ESI treatment (cf. Figures 1C and 2B). In
addition, cpd A induced phosphorylation of eIF2α and reduced the
rate of translation (Figures 2C and 2D), demonstrating that both
the IRE1 and PERK branches of the UPR were activated. This
effect of the cyclodepsipeptide inhibitors has not previously been
reported and supports the view that inhibiting Sec61-mediated
translocation promotes ER stress. This effect could potentially
be caused by the reduced biogenesis of specific ER factors such
as chaperones, some of which are known to be relatively short-
lived [24,25]. However, the global inhibition of protein synthesis
using CHX did not induce Xbp1 splicing (Figure 2E, lane 5),
suggesting that a lack of ER components resulting from a defect in
co-translational translocation is unlikely to underlie the ability of
ESI and cpd A to activate the UPR. These observations raised the
possibility that the induction of ER stress by these translocation
inhibitors might instead be related to the production of non-
translocated forms of membrane and secretory proteins. In order
to address this issue further, we examined the fate of various
ER-targeted proteins in the presence of ESI.
c© The Authors Journal compilation c© 2012 Biochemical Society
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Figure 2 Inhibition of translocation promotes ER stress
(A) HeLa cells were incubated with DMSO, 8 μM ESI, 10 μM PS2, 10 μM MG132 or 0.4 μM of the deubiquitinase inhibitor NSC687852 (NSC) for 8 h. Xbp1 mRNA splicing was determined by
RT–PCR. Products corresponding to unspliced (u) and spliced (s) Xbp1 mRNA are indicated. (B) HeLa cells were incubated with DMSO or the indicated concentration of the translocation inhibitor
cpd A for 8 h, and Xbp1 splicing was determined as above. (C) HeLa cells were incubated with DMSO or 10 μM cpd A for 8 h, and lysates were analysed by blotting with anti-peIF2α (phospho-eIF2α)
or anti-eIF2α antibodies. (D) HeLa cells were incubated with DMSO or 10 μM cpd A for 8 h, pulse-labelled with [35S]Met/Cys for 40 min, and lysates were analysed by phosphorimaging (top panel)
or blotting with an anti-tubulin antibody (bottom panel). Molecular mass in kDa is indicated on the left-hand side. (E) HeLa cells were incubated with 2 mM DTT for 2 h, DMSO for 8 h, 8 μM ESI for
4 or 8 h, or 100 μg/ml CHX for 8 h. Xbp1 splicing was determined as above.
ESI induces mislocalization and degradation of membrane and
secretory proteins in cultured cells
Addition of N-linked glycans to polypeptides occurs within the
ER lumen and was thus used to provide a readout of TCRα
insertion into the ER (cf. [12,22]). In DMSO- and ESR35-treated
cells, FLAG–TCRα was efficiently N-glycosylated and migrated
as a species of approximately 48 kDa (Figure 3A, lanes 1 and 2).
As observed previously [12], levels of the N-glycosylated form
of TCRα were reduced in ESI-treated cells (Figure 3A, lane 4).
In addition, a more rapidly migrating species of the size expected
for the unglycosylated protein was found to accumulate after 8 h
of treatment with ESI (Figure 3A, lane 4). A similar, although less
pronounced, effect was seen upon ESII treatment (Figure 3A, lane
3). These observations indicate that ESI treatment results in the
production of a form of TCRα lacking N-glycosylation.
We next examined the effect of ESI on the subcellular
localization of a chimaeric secretory protein composed
of fluorescent mCherry fused to the ER-targeting sequence of
preprolactin (ppl–mCherry). In untreated cells, ppl–mCherry
was predominantly localized to the secretory pathway, as
demonstrated by the reticular and ribbon-like pattern of
fluorescence, typical of the ER and Golgi apparatus respectively
(Figure 3B, panel A). Cells were then treated with CHX to prevent
further protein synthesis and allow existing protein to exit the ER.
After washing to remove CHX, cells were incubated with ESI,
PS2 or a combination of ESI and PS2 for a further 6 h, prior to
imaging. This treatment regime (outlined in Figure 3B) allowed
us to determine the localization of ppl–mCherry synthesized in
the presence of ESI. ppl–mCherry fluorescence was considerably
lower after 3 h of CHX treatment, confirming that much of the
protein had been secreted from the cells (Figure 3B, panel B).
In cells treated with PS2 alone following CHX treatment, the
ppl–mCherry distribution was similar to that in untreated cells
(Figure 3B, cf. panels A and C), suggesting that the majority of the
protein synthesized under conditions of proteasome inhibition was
correctly targeted to the ER. A different pattern of fluorescence
was seen in cells treated with ESI (Figure 3B, panel D). Under
these conditions, the reticular distribution of ppl–mCherry was
replaced by more diffuse fluorescence distributed throughout the
cell, suggesting that a proportion of the newly synthesized protein
had not entered the ER, but was instead located in the cytosol. A
variable amount of mCherry fluorescent protein was also observed
in punctate structures adjacent to the nucleus (Figure 3B, panels
D and E). Co-treatment with PS2 resulted in a much clearer
accumulation of fluorescent protein in the cytosol (Figure 3B,
panel E), suggesting that ppl–mCherry which failed to enter the
ER in the presence of ESI was degraded via the proteasome.
To validate these data, we took a complementary biochemical
approach to explore the fate of a polytopic membrane protein
synthesized in the presence of ESI. Membranes isolated from
HeLa cells transiently expressing opsin were extracted with
sodium carbonate, pH>11, to remove peripherally associated
proteins [26]. Membrane-integrated proteins are resistant to such
treatment, and were re-isolated by centrifugation, then solubilized
in Triton X-100. This method allowed separation of the ER lu-
menal chaperone PDI (Figure 3C, lane 3), from the integral ER
membrane protein derlin-1, which remained in the membrane-
associated pellet after carbonate extraction (Figure 3C, lanes
4 and 5). p97, which is peripherally associated with the ER
membrane, was removed in the carbonate supernatant (Figure 3C,
lane 3), confirming that this treatment effectively strips non-
integral proteins from the ER membrane. Next, cells treated with
DMSO, ESI, ESII or ESR35 for 1 h were pulse-labelled in the
continued presence of the compounds plus PS2, prior to carbonate
extraction and opsin IP. In untreated cells, the large majority of the
radiolabelled opsin was present in the carbonate-resistant pellet
(Figure 3D, lanes 2 and 3, DMSO), demonstrating that it was
stably integrated into the ER membrane. A smaller proportion
of the radiolabelled non-glycosylated opsin was extracted in
the carbonate supernatant (Figure 3D, lane 1, DMSO), probably
reflecting protein that failed to be correctly integrated into the ER
membrane. A similar distribution of opsin was seen in ESII- and
ESR35-treated cells (Figure 3D, ESII and ESR35). In the presence of
ESI, however, radiolabelled opsin was almost exclusively found in
the carbonate supernatant and was non-glycosylated (Figure 3D,
lane 1, ESI). Virtually no radiolabelled opsin could be detected in
the sodium carbonate-extracted pellet and there was no indication
of any glycosylated protein chains (Figure 3D, lanes 2 and 3,
ESI), suggesting that ESI inhibited the integration of opsin into
the ER membrane, leading to production of non-glycosylated
protein. Notably, the population of non-glycosylated opsin was
only readily apparent in HeLa cells when PS2 was included during
the pulse-labelling period (Figure 3E, cf. lanes 5 and 9), showing
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Figure 3 ESI causes mislocalization of membrane and secretory proteins
(A) HeLa cells expressing FLAG–TCRα were treated with DMSO or 8 μM ESR35, ESII or ESI for 8 h. Cell lysates were analysed by blotting with an anti-FLAG antibody. The position of glycosylated
(TCRα.CHO) and unglycosylated (TCRα) FLAG–TCRα are indicated. (B) HeLa cells expressing ppl–mCherry were left untreated (NT) or incubated with CHX for 3 h, then washed and treated with
8 μM ESI, 10 μM PS2, or 8 μM ESI and 10 μM PS2 for 6 h. Cells were fixed in methanol and visualized by fluorescence microscopy. Scale bar, 10 μm. (C) HeLa cells were lysed in hypotonic
buffer, total membranes were isolated and extracted with NaCO3, pH 11, and the resulting membrane fraction was solubilized with Triton X-100 (TX100). Samples of the total lysate (cell total), and
the supernatant (S) and pellet (P) fractions at each step were analysed by blotting with anti-PDI, anti-derlin-1 and anti-p97 antibodies. In (A and C), the molecular mass in kDa is indicated on the
left-hand side. (D) HeLa cells transiently expressing opsin were treated for 1 h with DMSO or 8 μM ESR35, ESII or ESI, plus 10 μM PS2, then labelled with [35S]Met/Cys for 40 min. Cells were
fractionated as in (B), and opsin was immunoprecipitated from each fraction and analysed by phosphorimaging. (E) HeLa cells transiently expressing opsin were treated with DMSO or 8 μM ESR35,
ESII or ESI for 1 h in the absence ( − ) or presence ( + ) of 10 μM PS2, then labelled with [35S]Met/Cys. Opsin was immunoprecipitated and analysed by phosphorimaging.
that proteins prevented from entering the ER upon ESI treatment
are normally subjected to proteasomal degradation.
Taken together, these results support a model whereby an
inhibition of translocation by ESI leads to the production of
mislocalized membrane and secretory proteins in cultured cells.
The non-translocated forms of ppl–mCherry and opsin that failed
to enter the ER in the presence of ESI were degraded via the
proteasome, suggesting that such polypeptides are targeted to
the UPS. We therefore postulated that the polyubiquitinated
species observed in ESI-treated cells (Figure 1A; see also
[8]), may include a variety of polypeptides that had failed to
translocate correctly across the ER membrane and were en route
to proteasomal degradation. Indeed, treatment of cells with ESII,
which has only a minor effect on protein translocation [12], caused
a less pronounced accumulation of polyubiquitinated material
(Figure 1A and Supplementary Figure 2C). Furthermore, we
found that treatment with the cyclodepsipeptide translocation
inhibitor cpd A also resulted in some accumulation of high-
molecular-mass polyubiquitinated material (Figure 4A, lane 3).
This previously unreported effect of cpd A provides additional
evidence that inhibition of ER translocation in live cells promotes
a build-up of polyubiquitin conjugates. Significantly, co-treatment
of cells with CHX completely prevented the accumulation of
polyubiquitin adducts caused by both cpd A and ESI (Figure 4A,
lane 4, and Figure 4B, lanes 4 and 5). This requirement for ongoing
protein synthesis suggests that these species represent proteins
newly synthesized in the presence of the translocation inhibitors.
In contrast, PS2 still caused accumulation of polyubiquitinated
proteins in the presence of CHX (Figure 4B, lanes 8 and 9),
suggesting that a significant proportion of these adducts were
derived from pre-existing proteins. We also found that treatment
with ESI led to the appearance of higher-molecular-mass forms
of EDEM-1 (ER degradation-enhancing α-mannosidase-like 1),
a model ER-resident protein (Figure 4C, lane 2). These species
migrated as diffuse bands near the top of the polyacrylamide
gel, comparable with the polyubiquitin conjugates detected
with anti-ubiquitin antibodies (Figure 4B). However, they were
not observed in cells treated with PS2 (Figure 4C, lane 3),
showing that they were not generated solely as a consequence
of inhibiting proteasomal degradation. Accumulation of these
higher-molecular-mass forms of EDEM-1 was prevented by co-
treatment with CHX (Figure 4C, lane 6), showing that they
represent polypeptides synthesized in the presence of ESI and
not an ESI-dependent modification of a pre-existing pool of
EDEM-1 (cf. [27]). On the basis of these results, we conclude
that the polyubiquitinated species induced by ESI and cpd A
most probably include non-translocated membrane and secretory
proteins targeted for proteasomal degradation. Supporting this
interpretation, endogenous ESI-induced polyubiquitin conjugates
were eliminated by cells following addition of CHX and a
subsequent chase period (Figure 4D). However, since PS2
rapidly induces accumulation of polyubiquitinated proteins even
in the presence of CHX (Supplementary Figure S4B), it
was not possible to demonstrate that the loss of ESI-induced
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Figure 4 Translocation inhibitors induce polyubiquitination of newly synthesized proteins
(A) HeLa cells were treated with DMSO, 10 μM PS2, 10 μM translocation inhibitor cpd A, or 10 μM cpd A and 100 μg/ml CHX for 8 h. Lysates were analysed by blotting with an anti-ubiquitin
(Ub) antibody. (B) HeLa cells were treated with DMSO, 8 μM ESI or 10 μM PS2 in the presence or absence of 100 μg/ml CHX for 4–8 h. Lysates were analysed by blotting with the anti-
ubiquitin antibody. (C) HeLa cells expressing EDEM1–Myc were treated with DMSO, 8 μM ESI, 10 μM PS2, 8 μM ESI and 10 μM PS2, 100 μg/ml CHX, or 8 μM ESI and 100 μg/ml CHX for
8 h. Lysates were analysed by blotting with an anti-Myc antibody. The position of full-length EDEM is indicated, and a Myc-cross-reacting species is indicated by O. Additional smaller product(s)
marked * disappeared when cells were treated with CHX and may represent unstable fragments of EDEM–Myc. (D) HeLa cells were incubated with 8 μM ESI for 4 h, washed and then incubated with
10 μg/ml CHX for 1–5 h to prevent further protein synthesis. Equal quantities of cell lysate were analysed by blotting with the anti-ubiquitin antibody. IB, immunoblot. The molecular mass in kDa is
indicated on the left-hand side.
polyubiquitin conjugates was proteasome-dependent. Therefore
we cannot exclude the possibility that this effect is the result of
deubiquitination of the substrates rather than degradation.
Inhibition of protein translocation contributes to the cellular
actions of ESI
Non-translocated membrane and secretory proteins have poten-
tially harmful properties, such as hydrophobic transmembrane
domains and/or uncleaved signal peptides. Therefore we
wondered whether the accumulation of such aberrant polypeptides
could contribute to the cellular effects of ESI and cpd A. To address
this issue, we exploited the observation that non-translocated
polypeptides accumulated to a greater extent when proteasome
activity is inhibited (Figure 3), whereas their production is
effectively blocked by CHX (Figure 4). This allowed us to
examine whether the ability of ESI and cpd A to induce ER
stress was altered by conditions that promoted or inhibited the
accumulation of non-translocated polypeptides. When protein
synthesis was prevented by co-treatment with CHX, both Xbp1
mRNA splicing and the ER vacuolization induced by ESI
were completely abolished (Figure 5A, lanes 5 and 7, and
Supplementary Figure 4C). Similarly, CHX also substantially
diminished Xbp1 splicing in response to cpd A (Figure 5B,
lanes 3 and 5). In contrast, the ability of DTT to induce Xbp1
splicing was not prevented by CHX (Figure 5A, lanes 3 and 4),
demonstrating that activation of this pathway is not dependent
on the continued import of cargo proteins into the ER, nor
mechanistically on protein synthesis itself. Thus activation of the
UPR by both ESI and cpd A requires ongoing translation. This is
an important finding as it suggests that polypeptides synthesized in
the presence of these compounds are responsible for their ability
to induce ER stress. In contrast, combinatorial treatment with
ESI and proteasome inhibitors more effectively induced Xbp1
splicing (Figure 5C, lanes 5 and 6, and Supplementary Figure
S4D) and enhanced ER vacuolization (Supplementary Figure
S4E) when compared with ESI alone. The ability of cpd A to
induce Xbp1 splicing was also increased by proteasome inhibition
(Figure 5B, lanes 3 and 4). Thus conditions that inhibit the efficient
degradation of non-translocated proteins (Figure 3) enhance the
ability of ESI and cpd A to activate the UPR, supporting
the hypothesis that accumulation of polyubiquitinated non-
translocated proteins promotes activation of the UPR. Consistent
with this interpretation, the accumulation of polyubiquitinated
proteins in ESI-treated cells correlated well with the induction of
ER stress (cf. Figures 1B and 1E).
On the basis of these findings, we propose a working model for
the cellular actions of ESI. In this model (Figure 6), a proportion
of nascent membrane and secretory proteins fail to enter the ER
in the presence of ESI or cpd A, and are instead polyubiquitinated
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Figure 5 Correlation between accumulation of mistranslocated polypeptides and induction of ER stress
(A) HeLa cells were treated with 100 μg/ml CHX for 8 h, 2 mM DTT and CHX for 2 h or 8 h, or with 8 μM ESI or 10 μM PS2 in the presence or absence of 100 μg/ml CHX for 8 h. Xbp1 splicing was
determined by RT–PCR. PCR products corresponding to unspliced (u) and spliced (s) Xbp1 mRNA are indicated. (B) HeLa cells were treated with DMSO, 2 mM DTT, or the indicated combination
of 10 μM translocation inhibitor cpd A, 10 μM PS2 and 100 μg/ml CHX for 8 h. Xbp1 splicing was determined by RT–PCR. (C) HeLa cells were incubated with DMSO, 8 μM ESI, 10 μM PS2,
10 μM MG132, 8 μM ESI and 10 μM PS2, or 8 μM ESI and 10 μM PS2 for 8 h. Xbp1 splicing was determined by RT–PCR.
Figure 6 Proposed model for cellular actions of ESI
Proteins possessing an ER signal sequence are targeted to the ER and translocated through the Sec61 translocon (1). Properly folded proteins exit the ER and move along the secretory pathway.
Misfolded proteins are retained by the ER quality control machinery (ER-QC) (2), handed over to the retrotranslocation machinery, polyubiquitinated and retrotranslocated (2). The retrotranslocated
protein is deubiquitinated and deglycosylated (3) before being degraded by the proteasome. Accumulation of misfolded proteins in the ER lumen activates UPR signalling. ESI inhibits translocation
of proteins across the ER membrane, leading to the production of non-translocated proteins (NTP) at the cytosolic face of the ER membrane. These aberrant species are degraded by the UPS and
also activate the UPR through an unknown mechanism. ESI may also inhibit one or more steps of the ERAD pathway, including retrotranslocation or deubiquitination. Also shown are the points of
action of CHX, PS2 and NSC687852 (NSC), a deubiquitinase inhibitor that induces accumulation of polyubiquitin in cells [18].
and may be subjected to proteasomal degradation. Since ESI and
cpd A only activate Xbp1 splicing if protein synthesis is ongoing,
we suggest that accumulation of these non-translocated proteins
in the cytosol contributes to activation of the ER stress response.
DISCUSSION
ER protein folding and degradation pathways have emerged as
exciting targets for the treatment of a diverse array of diseases,
from cancer and stroke to classical protein folding diseases. As
a result, there is much interest in the therapeutic potential
of selective small molecules to modulate ER protein folding
homoeostasis and the ER stress response. In the present study
we describe the preparative synthesis and cellular activity of
the ERAD inhibitor ESI and two related compounds ESII and
ESR35. We confirm that ESI inhibits ERAD of TCRα, causes
accumulation of polyubiquitinated proteins, and rapidly induces
ER stress. We also show that ESI reduces the efficiency of
protein translocation at the ER in cultured cells, and provide
evidence that membrane and secretory proteins that fail to enter
the ER in the presence of ESI are subjected to proteasomal
degradation. Using a second small-molecule inhibitor of co-
translational translocation, we examine the consequences of
reduced translocation efficiency in cultured cells. Intriguingly,
our results suggest that the accumulation of non-translocated
membrane and secretory proteins promotes activation of the ER
stress response.
Originally identified as an ERAD inhibitor, ESI was sub-
sequently found to impair Sec61-mediated protein translocation
at the ER for a range of substrates [12]. In the present study, we
have employed different techniques to show that ESI also perturbs
the entry of a variety of proteins into the ER of living cells.
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Thus the N-glycosylation of TCRα, the membrane integration
and N-glycosylation of opsin, and the ER localization of
ppl–mCherry were all impaired by treatment of cells with
ESI. In the presence of ESI, non-glycosylated TCRα, non-
integrated opsin and non-ER-localized ppl–mCherry continued
to be synthesized, and could be observed in ESI-treated cells.
However, the amount of these non-translocated species that
accumulated in cells following ESI treatment was somewhat
variable. These variations may reflect differences in the response
of different cell types to ESI treatment, for example greater
translational attenuation in HEK-293 cells, but could also be due
to differences in the degree of translocation inhibition caused
by ESI. Indeed, non-translocated forms of membrane proteins,
including TCRα and MHC class I heavy chain, were not observed
in previous studies [7,9], suggesting that ESI-mediated inhibition
of translocation is incomplete and/or can be influenced by
experimental variables such as the duration of drug treatment.
The non-translocated species we observed in ESI-treated
cells were labile, and inhibitor studies indicate that they are
degraded by the proteasome. Similarly, the cytosolic form of
the VCAM1 (vascular cell adhesion molecule 1) precursor
generated in the presence of translocation inhibitor cpd A is
also normally degraded via a proteasome-dependent pathway
[20]. Other non-translocated proteins generated under various
conditions of reduced translocation efficiency are also rapidly
removed by the proteasome [22,28,29]. Taken together, these
observations strongly support the existence of an efficient cellular
quality control system that functions to eliminate proteins that
fail to be properly translocated across the ER membrane. Indeed,
recent work has begun to identify the cytosolic machinery
involved in such a pathway [30]. Non-translocated species will
typically expose hydrophobic transmembrane domains and/or
uncleaved signal peptides, and it is easy to envisage that their
accumulation in the cytosol might be particularly harmful. Indeed,
aberrant interactions of non-translocated prion protein have been
proposed to contribute to neurodegeneration in prion diseases
[31,32]. Our results suggest that non-translocated polypeptides
may also participate in cellular dysfunction by promoting ER
stress. Thus we find that both ESI and another small-molecule
inhibitor of co-translational translocation induce accumulation of
polyubiquitinated proteins and activate the UPR. Strikingly, co-
treatment with CHX, which blocks accumulation of polyubiquitin
adducts, also abolishes the ER stress response induced by
these compounds. This requirement for ongoing translation
suggests that it is actually the polyubiquitinated non-translocated
polypeptides synthesized in the presence of the inhibitors that
promote activation of the UPR. In support of this model, the
ability of both ESI and cpd A to induce ER stress is enhanced
under conditions of proteasome inhibition that prevent efficient
degradation of non-translocated proteins. Our working model
(Figure 6) is consistent with the known actions of ESI and
cpd A, and would also explain the previously observed synergy
between ESI and the proteasome inhibitor bortezomib [10].
Although we cannot formally exclude the possibility that ESI
and cpd A activate the UPR by ‘off-target’ (ie. non-translocon)
effects, the facts that they are structurally distinct and inhibit
different stages of co-translational translocation suggest that this
is unlikely. Furthermore, the observation that CHX prevents UPR
activation in response to ESI and cpd A, but does not affect
DTT-induced UPR, suggests that the translocation inhibitors do
not induce ER stress through a direct effect on ER chaperones,
ERAD machinery or UPR components [7,27,33]. In addition
to perturbing ER translocation, ESI also inhibits p97 and an
associated deubiquitinase activity [9,10]. Interfering with p97
function is known to inhibit ERAD and can also induce swelling
of the ER (cf. [34]). It thus seems likely that reduced p97 function
may also contribute to the pronounced ER stress phenotype
induced by ESI. However, the ability of a second small-molecule
inhibitor of the Sec61 translocon to recapitulate many features of
ESI-induced UPR activation supports a model whereby products
of failed translocation promote ER stress.
Since the UPR is typically triggered by the presence of
misfolded proteins in the ER lumen, it is not immediately
obvious how the generation of non-translocated polypeptides in
the cytosol might promote this pathway (Figure 6). One potential
explanation is that polyubiquitination of these species reduces
the availability of free ubiquitin, thereby indirectly inhibiting
removal of misfolded proteins from the ER and inducing the
UPR. This would be consistent with the suggestion that inhibition
of deubiquitination by ESI causes a global ubiquitin deficiency
[10]. However, several distinct inhibitors of the UPS, namely PS2,
MG132 and NSC687852, failed to induce Xbp1 mRNA splicing
despite causing comparable accumulation of polyubiqitinated
material. On this basis, we believe that perturbation of ubiquitin
homoeostasis is not the underlying cause of ESI-induced UPR.
Non-translocated proteins could also disrupt protein homoeostasis
in the cytosol, for example by sequestering molecular chaperones.
Cytosolic chaperones such as Hsp70 (heat-shock protein 70)
play an important role in the biogenesis of some membrane
proteins [35], and therefore interfering with their function may
perturb folding at the ER and promote ER stress. Alternatively,
the accumulation of non-translocated polypeptides, which have a
high propensity to aggregate and initiate non-native interactions,
at the cytosolic face of the ER could potentially interfere with
the removal of misfolded proteins from the ER. This would
result in a build-up of misfolded proteins in the lumen and
activation of the UPR, and is consistent with the suggestion
that ESI inhibits retrotranslocation [7]. Indeed, certain misfolded
cytosolic proteins have been shown to engage in inappropriate
interactions with cytosolically oriented components of the ERAD
machinery, thereby inhibiting retrotranslocation and activating
the UPR [36,37]. We speculate that perturbation of such an early
stage in the ERAD process may have a particularly severe effect on
levels of misfolded proteins in the ER lumen and hence ER stress.
In contrast, inhibition of the proteasome does not always block
retrotranslocation, and several ERAD substrates can still exit
the ER when the proteasome is inhibited [38–41]. Alternatively,
non-translocated polypeptides may also activate UPR signalling
through some other, as yet undefined, mechanism [33,42].
The possibility that modulating protein translocation at the ER
might have therapeutic potential is further supported by the
finding that apratoxin A, a cyclodepsipeptide with anticancer
properties [43], inhibits co-translational translocation [44]. In this
case, depletion of cancer-associated transmembrane receptors was
proposed to underlie the cytotoxic activity of apratoxin A towards
cancer cells [44]. Thus the results of the present study further
extend the prospect that inhibitors of ER translocation may offer
novel therapeutic opportunities in the future, and underline the
potential for using small-molecule inhibitors to understand
the consequence of defects in membrane translocation events
at the cellular level [45].
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EXPERIMENTAL
Synthetic protocols
The synthesis of ESI and ESII commences with nitroso-compound
1, which was prepared according to a previous procedure by
reaction of isobutene with nitrosyl chloride (generated in situ from
isoamyl nitrite and HCl) [1]. Displacement of the chlorine atom in
1 by the amino group of methyl glycinate then proceeded smoothly
to give oximino ester 2 at a very good yield [2]. Exposure of 2
to two equivalents of its corresponding isocyanate gave the bis-
adducts [3] 3 and 4, which were subsequently converted into their
acyl hydrazides 5 and 6 by treatment with an aqueous methanolic
solution of hydrazine. Finally, coupling to commercially available
(E)-3-(5-nitro-2-furyl)acrylaldehyde gave ESI and ESII (7 and 8
respectively).
General experimental
Synthetic reagents were purchased from Sigma–Aldrich or Alfa
Aesar and used as supplied. Solvents were dried and distilled
prior to use. IR spectra were recorded on a PerkinElmer 881
spectrometer, an AT1-Matson Genesis Series FTIR (Fourier-
transform infrared) spectrometer or a PerkinElmer Spectrum BX
FTIR spectrometer. 1H and 13C spectra were recorded on a Bruker
Avance II 500 MHz spectrometer, a Bruker Avance III 400 MHz
spectrometer or a Bruker Avance 300 MHz spectrometer.
Chemical shifts are referenced to the residual solvent peak. Mass
spectra were recorded on a Micromass Platform II (electrospray)
spectrometer. Melting points were recorded using a Sanyo
Gallenkamp MPD350 heater and are uncorrected.
Methyl 2-[(2-hydroxyamino-1,1-dimethylethyl)amino]acetate (2)
Glycine methyl ester hydrochloride (5.17 g, 41 mmol) was
added, under an atmosphere of nitrogen, to a solution of 2-
chloro-2-methyl-1-nitrosopropane (1) (5.0 g, 41 mmol) in freshly
distilled acetonitrile (80 ml). Triethylamine (8.3 ml, 82 mmol)
was then added dropwise. The reaction mixture was stirred at
room temperature for 18 h and then quenched by the addition
of a saturated aqueous solution of sodium bicarbonate (40 ml).
Organic material was extracted into dichloromethane (4×50 ml)
and the combined organic layers were then washed with brine
(40 ml), dried over magnesium sulfate and concentrated under
reduced pressure to yield the title compound as a pale yellow solid
(5.75 g, 80%). Mp 86–86.9 ◦C; νmax (film)/cm− 1 3292 (m), 3163
(m), 3081 (m), 2977 (m), 2874 (m), 2798 (m), 1750 (s); δH (CDCl3:
300 MHz) 7.28 (1H, s, CH = NOH), 3.73 (3H, s, CO2CH3), 3.39
(2H, s, NCH2CO2CH3), 1.27 [6H, s, C(CH3)2]; δC (CDCl3: 125
MHz) 172.7 (CO2CH3), 154.8 (CH = NOH), 54.1 [C(CH3)2], 52.0
(CO2CH3), 44.7 (NCH2CO2CH3), 25.2 [C(CH3)2]; m/z (positive
ion electrospray) 197 ([M + Na]+ , 100%); (found 197.0899,
C7H14N2NaO3 ([M + Na]+ ), requires 197.0897).
Methyl 2-{3-(4-chlorophenyl)-4-[3-(4-chlorophenyl)-1-
hydroxyureido]-5,5-dimethyl-2-oxoimidazolidin-1-
yl}acetate (3)
A solution of 4-chlorophenyl isocyanate (1.01 g, 5.75 mmol)
in freshly distilled tetrahydrofuran (2 ml) was added under an
atmosphere of nitrogen to a solution of oxime (2) (0.57 g,
2.87 mmol) in tetrahydrofuran (14 ml). The resulting solution
was stirred at room temperature for 18 h and then concentrated
under reduced pressure. The product was crystallized from
dichloromethane, collected by filtration, washed with diethyl
ether and dried. The filtrate was concentrated under reduced
pressure and the crystallization procedure was repeated a further
three times. Combination of the batches of crystallized product
gave the title compound as a colourless solid (1.03 g, 65%).
Mp 217.5–218.8 ◦C; νmax (solid state)/cm− 1 3320 (m), 3285 (m),
2980 (w), 1735 (s), 1695 (s), 1672 (s), 1590 (m), 1526 (s), 1494
(s); δH (CDCl3: 500 MHz) 8.14 (1H, brs, NH or OH), 7.94 (1H,
brs, NH or OH), 7.66 (2H, d, J = 8.8 Hz, Ar-CH), 7.53 (2H,
d, J = 8.8 Hz, Ar-CH), 7.24–7.28 (4H, m, Ar-CH), 6.18 (1H, s,
NCHN), 4.40 (1H, d, J = 18.1 Hz, CHaHbCO2CH3), 3.59 (1H, d,
J = 18.1 Hz, CHaHbCO2CH3), 3.58 (3H, s, CO2CH3), 1.36 (3H, s,
CH3CCH3), 1.30 (3H, s, CH3CCH3); δC (CDCl3: 75 MHz) 172.6
(CO2CH3), 156.8, 155.8 [2×N(C = O)N], 137.2 (Ar-C), 136.9
(Ar-C), 129.1 (2×Ar-CH), 128.9 (Ar-C), 128.8 (2×Ar-CH), 128.2
(Ar-C), 121.0 (2×Ar-CH), 120.3 (2×Ar-CH), 74.7 (NCHN),
59.0 (CH3CCH3), 53.0 (CO2CH3), 40.6 (CH2CO2CH3), 26.4
(CH3CCH3), 19.3 (CH3CCH3); m/z (negative ion electrospray)
481.3 ([M − H]− {35Cl, 37Cl}, 65%), 479.5 ([M − H]−{35Cl,
35Cl}, 100%); (positive ion electrospray) 505 ([M + Na]+ {35Cl,
37Cl}, 60%), 503 ([M + Na]+ {35Cl, 35Cl}, 100%); (found
503.0847, C21H2235Cl2N4NaO5 ([M + Na]+ ), requires 503.0859).
3-(4-Chlorophenyl)-1-[3-(4-chlorophenyl)-1-(2-hydrazinyl-2-
oxoethyl)-5,5-dimethyl-2-oxoimidazolidin-4-yl]-1-hydroxyurea (5,
ESR35)
An aqueous solution of hydrazine (62%, 1.18 ml, 24 mmol) was
added to a solution of imidazolidinone (3) (0.567 g, 1.18 mmol)
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in methanol (6 ml). The reaction mixture was stirred at room
temperature for 48 h and then cooled to 0 ◦C. The resulting
precipitate was collected by filtration, washed sequentially with
cold methanol (10 ml) and diethyl ether (10 ml) and dried to yield
the title compound as a colourless solid (0.358 g, 63%). Mp
197.5–199 ◦C; νmax (solid state)/cm− 1 3304 (m), 3085 (m), 3029
(m), 1700 (s), 1649 (m), 1647 (m), 1591, (m), 1527 (s), 1493
(s); δH (CD3OD: 500 MHz) 7.68 (2H, d, J = 8.8 Hz, Ar-CH),
7.46 (2H, d, J = 8.8 Hz, Ar-CH), 7.33 (2H, d, J = 8.8 Hz, Ar-
CH), 7.28 (2H, d, J = 8.8 Hz, Ar-CH), 6.12 (1H, s, NCHN), 4.08
(1H, d, J = 17.3 Hz, CHaHbCONHNH2), 3.82 (1H, d, J = 17.3
Hz, CHaHbCONHNH2), 1.41 (3H, s, CH3CCH3), 1.35 (3H, s,
CH3CCH3); δC (CD3OD: 125 MHz) 171.5 [C( = O)NHNH2]
159.0, 158.5 [2×N(C = O)N], 138.8 (Ar-C), 138.4 (Ar-C), 130.3
(Ar-C), 130.0 (Ar-C), 129.9 (2×Ar-CH), 129.8 (2×Ar-CH), 123.4
(2×Ar-CH), 122.6 (2×Ar-CH), 77.1 (NCHN), 61.1 (CH3CCH3),
42.4 [CH2(C = O)NHNH2], 25.7 (CH3CCH3), 19.4 (CH3CCH3);
m/z (negative ion electrospray) 481 ([M − H]− {37Cl, 35Cl},
65%), 479 ([M − H]− {35Cl, 35Cl}, 100%); (found 479.0998,
C20H2135Cl2N6O4, ([M − H]− ), requires 479.1007).
3-(4-Chlorophenyl)-1-[3-(4-chlorophenyl)-5,5-dimethyl-
1-(2-{(E)-2-[(E)-3-(5-nitrofuran-2-yl)allylidene]hydrazinyl}-2-
oxoethyl)-2-oxoimidazolidin-4-yl]-1-hydroxyurea (7, ESI)
(E)-3-(5-nitro-2-furyl)acrylaldehyde (0.063 g, 0.377 mmol) was
added under an atmosphere of nitrogen to a solution of acyl
hydrazide (5) (0.180 g, 0.377 mmol) in freshly distilled methanol
(2 ml). The resulting solution was stirred at room temperature for
18 h and then concentrated under reduced pressure. The product
was crystallized from dichloromethane, collected by filtration,
washed with cold dichloromethane (10 ml) and pentane (10 ml)
and dried, yielding the title compound as a yellow solid (0.191 g,
81%). Mp 211–213 ◦C; νmax (solid state)/cm− 1 3382 (w), 3124
(w), 2983 (m), 2890 (w), 1707 (m), 1669 (s), 1519 (s), 1494 (s);
δH (CDCl3: 500 MHz) 9.85 (1H, brs, NH or OH), 9.42 (1H, brs,
NH or OH), 7.68 (2H, d, J = 8.9 Hz, 2×Ar-CH), 7.65 (1H, brs,
NH or OH), 7.38 (2H, d, J = 8.9 Hz, 2×Ar-CH), 7.30–7.26 (3H,
m, CH = CHCH = N and 2×Ar-CH), 7.18 (1H, d, J = 3.6 Hz,
CHCH = CNO2), 7.16 (2H, d, J = 8.8 Hz, 2×Ar-CH), 6.95 (1H,
dd, J = 15.5 and 9.4 Hz, CH = CHCH = N), 6.34 (1H, d, J = 3.6
Hz, CHCH = CNO2), 6.13 (1H, s, NCHN), 5.47 (1H, brd, J = 15.5
Hz, CH = CHCH = N), 4.78 (1H, d, J = 18.3 Hz, CHaHbCONH),
4.11 (1H, d, J = 18.3 Hz, CHaHbCONH), 1.43 (3H, s, CH3CCH3),
1.30 (3H, s, CH3CCH3); m/z (negative ion electrospray) 630
([M − H]− , {35Cl, 37Cl}, 70%), 628 ([M − H]− , {35Cl, 35Cl},
100%); (found 628.1123, C27H2435Cl2N7O7 ([M − H]− ), requires
628.1120).
Methyl 2-{4-[1-hydroxy-3-(naphthalen-1-yl)ureido-5,5-dimethyl-3-
(naphthalen-1-yl)-2-oxoimidazolidin-1-yl]acetate} (4)
A solution of 1-naphthyl isocyanate (1.01 g, 5.75 mmol) in freshly
distilled tetrahydrofuran (2 ml) was added under an atmosphere
of nitrogen to a solution of oxime (2) (0.57 g, 2.87 mmol)
also in freshly distilled tetrahydrofuran (14 ml). The reaction
mixture was stirred at room temperature for 15 h, when residual
solvent was removed under reduced pressure. The product was
crystallized from dichloromethane, collected by filtration, washed
with diethyl ether (20 ml) and dried under vacuum. The filtrate
was concentrated under reduced pressure and the crystallization
procedure was repeated a further three times. Combination of the
crystallized material yielded the title compound as a colourless
solid (0.921 g, 61%). Mp 199–200 ◦C; νmax (solid state)/cm− 1
3436 (w), 3054 (brw), 2839 (brw), 1749 (s), 1658 (s), 1535 (s);
δH (CDCl3: 500 MHz) 8.17 (1H, brs, NH or OH), 8.08 (1H, brd,
J = 7.9 Hz, Ar-CH), 7.99 (1H, brs, NH or OH), 7.92 (1H, brd,
J = 6.7 Hz, Ar-CH), 7.87–7.78 (4H, m, 4×Ar-CH), 7.61 – 7.59
(2H, m, 2×Ar-CH), 7.55–7.52 (1H, m, Ar-CH), 7.50–7.44 (5H, m,
5×Ar-CH), 7.35-7.32 (1H, m, Ar-CH), 6.19 (1H, s, NCHN), 4.69
(1H, d, J = 18.2 Hz, CHaHbCO2CH3), 3.88 (3H, s, CO2CH3), 3.79
(1H, d, J = 18.2 Hz, CHaHbCO2CH3), 1.71 (3H, s, CH3CCH3),
1.49 (3H, s, CH3CCH3); m/z (negative ion electrospray) 511
([M − H]− , 100%): (positive ion electrospray) 535 ([M + Na]+ ,
100%); (found 535.1949, C29H28N4NaO5 ([M + H]+ ), requires
535.1952).
1-[1-(2-Hydrazinyl-2-oxoethyl)-5,5-dimethyl-3-(naphthalen-1-yl)-
2-oxoimidazolidin-4-yl]-1-hydroxy-3-(naphthalen-1-yl)urea (6)
An aqueous solution of hydrazine (62%, 0.88 ml, 23 mmol) was
added to a solution of imidazolidinone, 4 (0.451 g, 0.88 mmol) in
methanol (4.5 ml). The reaction mixture was stirred at room tem-
perature for 48 h and then cooled to 0 ◦C. The resulting precipit-
ated solid was collected by filtration and washed sequentially with
cold methanol (10 ml) and diethyl ether (10 ml). The filtrate was
concentrated under reduced pressure and the residual solid was
recrystallized at room temperature from dichloromethane/diethyl
ether (1:1), washed with cold methanol and diethyl ether and
then combined with the first batch of precipitate to yield the title
compound as a colourless solid (0.248 g, 55%). Mp 195–197 ◦C;
νmax (film)/cm− 1 3390 (m), 3271 (brm), 3054 (m), 2971 (m),
2857 (brw), 1686 (s), 1596 (m), 1520 (m), 1495 (s); δH (CD3OD:
500 MHz) 8.12 (1H, brs, NH or OH), 7.98–7.95 (3H, m, 3×Ar-
CH), 7.80 (1H, d, J = 8.2 Hz, Ar-CH), 7.68 (1H, d, J = 8.2 Hz,
Ar-CH), 7.61–7.52 (4H, m, 4×Ar-CH), 7.45–7.30 (5H, m, 5×Ar-
CH), 6.99 (1H, d, J = 7.2 Hz, Ar-CH), 6.10 (1H, s, NCHN), 4.12
(1H, d, J = 16.8 Hz, CHaHbCONH), 3.96 (1H, d, J = 16.8 Hz,
CHaHbCONH), 1.70 (3H, s, CH3CCH3), 1.61 (3H, s, CH3CCH3);
m/z (negative ion electrospray) 511 ([M − H]− , 100%), (positive
ion electrospray) 535 ([M + Na]+ , 100%); (found 535.2065,
C28H28N6NaO4 ([M + Na]+ ), requires 535.2064).
1-(5,5-Dimethyl-3-(naphthalen-1-yl)-1-(2-((E)-2-((E)-3-(5-
nitrofuran-2-yl)allylidene)hydrazinyl-2-oxoethyl)-2-
oxoimidazolidin-4-yl)-1-hydroxy-3-(naphthalen-1-yl)urea
(8, ESII)
(E)-3-(5-nitro-2-furyl)acrylaldehyde (0.020 g, 0.120 mmol) was
added under an atmosphere of nitrogen to a solution of acyl
hydrazide (6) (0.070 g, 0.137 mmol) in freshly distilled methanol
(1 ml). The reaction solution was stirred at room temperature for
48 h and then concentrated under reduced pressure. The residue
was recrystallized at room temperature from ethyl acetate/diethyl
ether (1:2), yielding the title compound as a yellow solid (0.075 g,
83%). Mp 213–215 ◦C; νmax (solid state)/cm− 1 3410 (w), 3267
(m), 3013 (brm), 2862 (w), 1739 (brs) 1702 (s), 1655 (s), 1626
(m), 1537 (s); δH (CDCl3 + one drop of C5D5N: 400 MHz) 11.6
(brs, 1H, NH or OH), 7.97–7.95 (3H, m, 3×Ar-CH), 7.89–7.87
(1H, m, Ar-CH), 7.81–7.76 (1H, m, Ar-CH), 7.71–7.65 (2H,
m, 2×Ar-CH), 7.53–7.45 (10H, m, 10×Ar-CH), 7.28 (1H, d,
J = 2.9 Hz, CHCH = CNO2), 6.86 (1H, dd, J = 15.8 and 8.9 Hz,
CH = CHCH = N), 6.48 (1H, d, J = 2.9 Hz, CHCH = CNO2),
6.32 (1H, s, NCHN), 5.55 (1H, brs, NH or OH), 5.36 (1H,
d, J = 15.8 Hz, CH = CHCH = N), 4.59 (1H, d, J = 17.9 Hz,
CHaHbCONH), 1.67 (3H, s, CH3CCH3), 1.52 (3H, s, CH3CCH3);
m/z (negative ion electrospray) 660 ([M − H]− , 100%), (positive
ion electrospray) 684 ([M + Na]+ , 100%); (found 660.2199,
C35H30N7O7 ([M − H]− ), requires 660.2212).
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Figure S1 Synthesis of ESs
Scheme illustrating the synthesis of ESI, ESII and ESR35.
Figure S2 ESI inhibits ERAD
(A) HeLa cells transiently expressing FLAG–TCRα were pulse-labelled with [35S]Met/Cys for 40 min then chased in the presence of DMSO or 8 μM ESR35, ESII or ESI. FLAG–TCRα was
immunoprecipitated and analysed by SDS/PAGE and phosphorimaging. Glycosylated (TCRα.CHO) and unglycosylated (TCRα) FLAG–TCRα are indicated. Since cells were only exposed to the
compounds after pulse-labelling, the FLAG–TCRα was predominantly in the glycosylated form in each case. (B) HEK cells transiently expressing FLAG–TCRα were treated with DMSO, 8 μM ESI
or 10 μM PS2 for 8 h, then incubated with 100 μg/ml CHX for 0–3h. Lysates were analysed by Western blotting with an anti-FLAG antibody. (C) HEK cells were treated for 8 h with DMSO, 8 μM
ESR35, ESII or ESI, or 10 μM PS2, and lysates were analysed by blotting with an anti-ubiquitin antibody. IB, immunoblot.
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Figure S3 ESI activates the UPR in HEK cells
(A) HEK-293 cells were treated with 10 mM DTT for 30 min or 8 μM ESI for 0–6 h, then were labelled with [35S]Met/Cys for 40 min in the presence or absence of the respective compound. The total
time of exposure to ESI is indicated above each lane. Lysates were analysed by SDS/PAGE and phosphorimaging (top panels), or by blotting with anti-peIF2α or anti-eIF2α antibodies (bottom two
panels). (B) HEK-293 cells were left untreated (NT), or were treated with 2 mM DTT for 2 h or 8 μM ESI for the time indicated. Xbp1 mRNA splicing was determined by RT–PCR. Unspliced (u) and
spliced (s) Xbp1 mRNA are indicated.
Figure S4 Relationship between ESI and the UPS
(A) HeLa cells were treated with 8 μM ESR35 or ESI or 0.4 μM NSC687852 (NSC) for 8 h, and lysates were analysed by blotting with an anti-ubiquitin (Ub) antibody. (B) HeLa cells were treated
with DMSO for 4 h, 8 μM ESI or 10 μM PS2 with or without 100 μg/ml CHX for the times indicated, and lysates were analysed by blotting with the anti-ubiquitin antibody. N.B. Lanes 1–4 of this
experiment are also shown in Figure 1(B) in the main paper. Molecular mass in kDa is shown on the left-hand side. (C) HeLa cells were treated with DMSO, 8 μM ESI, or 8 μM ESI and 100 μg/ml
CHX for 8 h, then visualized by phase-contrast microscopy. Arrows indicate vacuolar structures. (D) HeLa cells were left untreated (NT) or treated with 2 mM DTT for 2 h, or with 8 μM ESI, 10 μM
PS2, or 8 μM ESI and 10 μM PS2 for the time indicated. Xbp1 mRNA splicing was determined by RT–PCR. Unspliced (u) and spliced (s) Xbp1 mRNA are indicated. (E) HeLa cells were treated with
8 μM ESI, 10 μM PS2, or 8 μM ESI and 10 μM PS2 for 8h, then visualized by phase contrast microscopy. Arrows indicate vacuolar structures.
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